Drug Approval | March 02, 2022
USFDA approves first generic version of Apokyn cartridges
TruPharma has commenced commercial marketing of Sage's approved generic cartridge product
TruPharma has commenced commercial marketing of Sage's approved generic cartridge product
To be marketed by Strides Pharma Inc. in the US market
The tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency
Clarithromycin tablets USP, 250 mg and 500 mg have an estimated market size of US $ 11 million for twelve months ending September 2021 according to IQVIA
The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval
Dronedarone tablets USP, 400 mg have an estimated market size of US $ 500 million for twelve months ending September 2021 according to IQVIA
Entacapone tablets USP, 200 mg have an estimated market size of US$ 10.5 million for twelve months ending September 2021, according to IQVIA
Doxycycline Hyclate Delayed Release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria
The tablets are available in 150 mg and 225 mg strengths in bottle count sizes of 30 and 90.
The tablets are indicated for the treatment of pulmonary arterial hypertension
Subscribe To Our Newsletter & Stay Updated
